ADCT - ADC Therapeutics SA
After hours:
Chart Events
Momentum
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 2.2800 |
| Open | 2.2800 |
| Bid | 0.0000 x 2200 |
| Ask | 3.3900 x 1800 |
| Day's Range | 2.2800 - 2.3700 |
| 52 Week Range | 1.8500 - 10.8800 |
| Volume | |
| Avg. Volume | 603,358 |
| Market Cap | 189.51M |
| Beta (5Y Monthly) | 1.11 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.3900 |
| Earnings Date | May 09, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 10.67 |
Fair Value
Related Research
Business WireADC Therapeutics Announces Updated Results from LOTIS-2 Trial to be Presented at the European Hematology Association 2023 Hybrid Congress
LAUSANNE, Switzerland, May 11, 2023--ADC Therapeutics SA (NYSE: ADCT) today announced updated results from LOTIS-2, the pivotal Phase 2 clinical trial of ZYNLONTA® (loncastuximab tesirine-lpyl) in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), have been accepted for presentation at the European Hematology Association 2023 Hybrid Congress (EHA2023), which will be held in Frankfurt, Germany from June 8-11, 2023.
Simply Wall St.These Analysts Think ADC Therapeutics SA's (NYSE:ADCT) Sales Are Under Threat
Today is shaping up negative for ADC Therapeutics SA ( NYSE:ADCT ) shareholders, with the analysts delivering a...
Business WireADC Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference
LAUSANNE, Switzerland, May 10, 2023--ADC Therapeutics SA (NYSE: ADCT) today announced that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the RBC Capital Markets Global Healthcare Conference in New York City on Tuesday, May 16th at 10:00 a.m. EDT.
- Simply Wall St.
ADC Therapeutics First Quarter 2023 Earnings: Misses Expectations
ADC Therapeutics ( NYSE:ADCT ) First Quarter 2023 Results Key Financial Results Revenue: US$19.0m (down 59% from 1Q...
ZacksADC Therapeutics SA (ADCT) Reports Q1 Loss, Misses Revenue Estimates
ADC Therapeutics SA (ADCT) delivered earnings and revenue surprises of 7.50% and 5.49%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
- Business Wire
ADC Therapeutics Reports First Quarter 2023 Financial Results and Provides Business and Strategy Update
LAUSANNE, Switzerland, May 09, 2023--ADC Therapeutics SA (NYSE: ADCT) today reported financial results for the first quarter 2023 and provided an updated corporate strategy.
ZacksXenon Pharmaceuticals (XENE) Expected to Beat Earnings Estimates: Should You Buy?
Xenon Pharmaceuticals (XENE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Business WireADC Therapeutics to Host First Quarter 2023 Financial Results Conference Call on May 9, 2023
LAUSANNE, Switzerland, May 02, 2023--ADC Therapeutics SA (NYSE: ADCT) today announced that it will host a conference call and live webcast on Tuesday, May 9, 2023 at 8:30 a.m. EDT to report financial results for the first quarter 2023 and provide business updates.
ZacksAnalysts Estimate ADC Therapeutics SA (ADCT) to Report a Decline in Earnings: What to Look Out for
ADC Therapeutics SA (ADCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Simply Wall St.
ADC Therapeutics SA (NYSE:ADCT) is definitely on the radar of institutional investors who own 34% of the company
Key Insights Institutions' substantial holdings in ADC Therapeutics implies that they have significant influence over...
ZacksSeres Therapeutics (MCRB) Moves 10.9% Higher: Will This Strength Last?
Seres Therapeutics (MCRB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Business WireADC Therapeutics Releases its Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2022
LAUSANNE, Switzerland, March 15, 2023--ADC Therapeutics SA (NYSE: ADCT) today announced its Annual Report on Form 20-F for the fiscal year ended December 31, 2022, has been filed with the U.S. Securities and Exchange Commission (the "SEC").
ZacksBioMarin (BMRN) Provides FDA Filing Update for Gene Therapies
The FDA accepts BioMarin's (BMRN) label-expansion filing for Voxzogo to treat children under five years with achondroplasia. The agency extends the review period for Roctavian BLA.
ZacksDown -36.18% in 4 Weeks, Here's Why ADC Therapeutics SA (ADCT) Looks Ripe for a Turnaround
ADC Therapeutics SA (ADCT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Insider MonkeyADC Therapeutics SA (NYSE:ADCT) Q4 2022 Earnings Call Transcript
ADC Therapeutics SA (NYSE:ADCT) Q4 2022 Earnings Call Transcript February 28, 2023 Operator: Welcome to the ADC Therapeutics Fourth Quarter and Full Year 2022 Financial Results Conference Call. My name is Andrew, and I’ll be your operator for today’s call. At this time, all participants are in listen-only mode. Later, we will conduct a question-and-answer […]
Business WireADC Therapeutics to Participate in the Cowen 43rd Annual Health Care Conference
LAUSANNE, Switzerland, March 01, 2023--ADC Therapeutics SA (NYSE: ADCT) announced today that Ameet Mallik, Chief Executive Officer, will present a company overview at the Cowen 43rd Annual Health Care Conference in Boston, MA, on Tuesday, March 7th at 2:50 p.m. ET.
ZacksADC Therapeutics SA (ADCT) Reports Q4 Loss, Misses Revenue Estimates
ADC Therapeutics SA (ADCT) delivered earnings and revenue surprises of 38.78% and 7.58%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Business WireADC Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates
LAUSANNE, Switzerland, February 28, 2023--ADC Therapeutics SA (NYSE: ADCT) today reported financial results for the fourth quarter and full year ended December 31, 2022, and provided business updates.
Business WireADC Therapeutics to Host Fourth Quarter and Year-End 2022 Financial Results Conference Call on February 28, 2023
LAUSANNE, Switzerland, February 21, 2023--ADC Therapeutics SA (NYSE: ADCT) today announced that it will host a conference call and live webcast on Tuesday, February 28, 2023 at 8:30 a.m. ET to report financial results for the fourth quarter and year-end 2022 and provide business updates.
Business WireADC Therapeutics Announces Pricing of Underwritten Offering by a Selling Shareholder
LAUSANNE, Switzerland, February 02, 2023--ADC Therapeutics SA ("ADCT" or the "Company") (NYSE: ADCT), a commercial-stage biotechnology company helping to improve the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates, today announced the pricing of an underwritten offering of 12,000,000 common shares of the Company currently owned by A.T. Holdings II Sàrl (the "Selling Shareholder"), an affiliate of Auven Therapeutics Holdings L.P., at a price of $5.00
Business WireADC Therapeutics to Participate in February Investor Conferences
LAUSANNE, Switzerland, February 01, 2023--ADC Therapeutics SA (NYSE: ADCT) announced today that Ameet Mallik, Chief Executive Officer, will participate in two investor conferences in February.
ZacksPliant Therapeutics (PLRX) Surges 44% in A Week: Here's Why
Shares of Pliant Therapeutics (PLRX) have been rising since management reported positive interim data from a mid-stage study evaluating a higher dose of its lead pipeline candidate in IPF patients.
- Zacks
Amarin Corporation (AMRN) Down 13% in One Week: Here's Why
Shares of Amarin Corporation (AMRN) fell last week as the company's largest shareholder pressurizes the company to make changes to its board of directors.
ZacksWall Street Analysts Think ADC Therapeutics SA (ADCT) Could Surge 174.2%: Read This Before Placing a Bet
The mean of analysts' price targets for ADC Therapeutics SA (ADCT) points to a 174.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
ZacksADC Therapeutics SA (ADCT) Stock Jumps 21.8%: Will It Continue to Soar?
ADC Therapeutics SA (ADCT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.